COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024

2June 17, 2024 Capital Markets Day 2024 Photos and video recordings of participants will be taken during this event. These may be used for future publications and marketing by QIAGEN, including their website and social media channels. For on-site participants: Be aware that sitting in the front row may result in being captured in photos or videos, primarily focused on the presenters on stage. If you prefer not to be featured in these media, please notify our colleagues at the registration desk. CAPITAL MARKETS DAY MICROSITE Webcast, presentation, infographic and additional information to be found here. Recording available after the event.

2024 QIAGEN CAPITAL MARKETS DAY AGENDA 3 12:00 – 12:10 Introduction 10 John Gilardi Vice President, Corporate Communications and Investor Relations 12:10 – 12:40 2028 strategy 30 Thierry Bernard Chief Executive Officer 12:40 – 13:00 Sample technologies and QIAcuity dPCR 20 Nitin Sood Senior Vice President, Life Sciences Business Area 13:00 – 13:20 QuantiFERON TB and QIAstat-Dx 20 Fernando Beils Senior Vice President, Molecular Diagnostics Business Area 13:20 – 13:35 Break 15 13:35 – 13:55 QIAGEN Digital Insights 20 Jonathan Sheldon Senior Vice President, QIAGEN Digital Insights Business Area 13:55 – 14:15 2028 targets 20 Roland Sackers Chief Financial Officer 14:15 – 14:45 Q&A session 30 June 17, 2024 Capital Markets Day 2024

TODAY'S PRESENTERS 4Capital Markets Day 2024June 17, 2024 Thierry Bernard Chief Executive Officer Thierry Bernard joined QIAGEN in 2015 to lead our growing presence in molecular diagnostics. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis, and became a member of the Managing Board in 2021. Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in other leading international companies. He was named in March 2023 as Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association. Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona, and has been appointed Conseiller du Commerce Extérieur by the French government. Roland Sackers Chief Financial Officer Roland Sackers has been Chief Financial Officer at QIAGEN since 2004 and a member of the Managing Board since 2006. He previously was an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Since 2019, Mr. Sackers has served on the Supervisory Board of Evotec SE, a publicly listed company based in Germany, becoming Chair of the Audit Committee in 2019 and Vice Chair of the Supervisory Board in 2021. He is also a member of the Board of the industry association BIO Deutschland. Mr. Sackers earned his Diplom-Kaufmann from the University of Münster.

TODAY'S PRESENTERS 5Capital Markets Day 2024June 17, 2024 Nitin Sood Senior Vice President, Life Sciences Nitin Sood joined QIAGEN in 2023 as Senior Vice President, Head of the Life Sciences Business Area, and member of the Executive Committee. He most recently served as Chief Commercial Officer, MRD, at Adaptive Biotechnologies. He has enjoyed a 20-year career in the diagnostic and life science fields, having also held leadership roles at Guardant Health, PerkinElmer, Agilent Technologies and NuGEN Technologies. He holds a Master’s degree from Delhi University in Molecular Biology and a Master’s degree from Ball State University in Computer Science. Fernando Beils Senior Vice President, Molecular Diagnostics Fernando Beils joined QIAGEN in 2023 as Senior Vice President, Head of the Molecular Diagnostics Business Area, and member of the Executive Committee. He has worked in various global leadership roles within the diagnostics industry during his career, and most recently served as Vice President and General Manager of the Genetic Testing Solutions Business at Thermo Fisher Scientific. Prior to this role, he spent over two decades at Siemens in commercial, strategy and finance roles, and in his last role as Global Head of the Molecular Diagnostics Business Unit at Siemens Healthineers. He earned a degree in Business Administration from EWA Madrid and the University Mosbach School of Business. Jonathan Sheldon Senior Vice President, QIAGEN Digital Insights Dr. Jonathan Sheldon joined QIAGEN in 2018 as Senior Vice President, Head of the QIAGEN Digital Insights Business Area. He leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights. Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as in software firms serving the life science and healthcare sectors. He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.

Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, adjusted diluted earnings per share results, expansion of adjusted operating income margin, returns to shareholders, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tax laws, regulatory processes and dependence on suppliers and logistics services); variability of operating results; integration of acquired businesses; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and rising interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results. 6June 17, 2024 Capital Markets Day 2024

2028 STRATEGY COMMITTED TO SOLID PROFITABLE GROWTH 7Capital Markets Day 2024June 17, 2024 Thierry Bernard Chief Executive Officer

THE VALUE OF BIOLOGY HAS NEVER BEEN STRONGER 8June 17, 2024 Capital Markets Day 2024 Direct impact on your lives Crucial to advancing science Improving healthcare for all

QIAGEN MORE FOCUSED AND STRONGER THAN EVER +7% non-COVID sales CAGR (2019-23) >60,000 annual mentions in academic journals ENHANCING GROWTH AND VALUE 9June 17, 2024 Capital Markets Day 2024 QIAGEN customers QIAGEN product groups Diagnostic solutions Genomics / NGS LIFE SCIENCES MOLECULAR DIAGNOSTICS Sample technologies PCR >85% highly recurring revenues >17,000 new instrument placements since 2019 ~$13-14 bn addressable market (2028) ~$11 bn addressable market (2024) ~4-6% CAGR CAGR – Compound annual growth rate Total addressable market based on QIAGEN estimates

WELL-BALANCED ACROSS KEY MARKET DIMENSIONS June 17, 2024 10 53% 47% Molecular Diagnostics Life Sciences 36% 34% 15%12% 3% Sample technologies Diagnostic solutions PCR / Nucleic acid amplification Genomics / NGS Other 88% 12% Consumables and related revenues (including bioinformatics) Instruments 52% 32% 16% Americas EMEA Asia-Pacific / Japan Customers Product groups Product types Regions Balanced portfolio Diversified product base Strong recurring revenues Global presence Capital Markets Day 2024 2023 net sales: ~$2 bn

LEVERAGING A TRUSTED BRAND KNOWN FOR QUALITY June 17, 2024 Capital Markets Day 2024 Pharma / CROs Public agencies Academia / hospitals Clinical labs / test facilities 11 CRO – Contract Research Organization Serving >500,000 customers from basic research to clinical testing

FROM ACADEMIA TO CLINICAL LABS, A CONTINUUM OF DIFFERENTIATED SOLUTIONS June 17, 2024 Capital Markets Day 2024 Samples Detection InsightsSample preparation Sample technologies Any biological sample 12 PCR Genomics / NGS Diagnostic solutions LIFE SCIENCES CUSTOMERS ~$5-6 bn total addressable market (2024) ~$5-6 bn total addressable market (2024) MOLECULAR DIAGNOSTICS CUSTOMERS Academic labs Government research labs Pharma / Biotech Forensics / Human ID Hospitals / Decentralized healthcare Reference labs Pharma partnerships Public health agencies

13Capital Markets Day 2024 STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH Sharpen focus on growth pillars to sustain profitable growth Drive efficiency and digitization to fuel growth investments and profitability Ensure disciplined capital allocation for growth and shareholder value Deliver through accountable, empowered and reinvigorated leadership BPS – Basis points CAGR – Compound annual growth rate CER – Constant exchange rates June 17, 2024 OUR 2028 TARGETS At least $2 bn net sales CER from pillars in 2028 At least 250 bps adj. operating income margin expansion 2024-28 At least $1 bn of returns to shareholders 2024-28 (absent M&A) ~7% Net sales CER CAGR (2024-28) ≥31% Adj. operating income margin CER (2028)

SHARPENING FOCUS ON PILLARS FOR PROFITABLE GROWTH 14 Our growth drivers: Sharpened focus on profitable growth // SHARPEN FOCUS ON GROWTH PILLARS NeuMoDx: Disciplined portfolio management June 17, 2024 Capital Markets Day 2024 # Current position Reduce commercial support in stages through 2025 Responsibly transition customers to other solutions Reinforce strategy of focused leadership Reallocate resources to other opportunities and improve profitability QIAGEN Digital Insights (QDI) Accelerate investments for growth QIAcuity dPCR PCR QIAstat-Dx Diagnostic solutions Genomics / NGS #2 #3 #1 Sample technologies QuantiFERON Build on proven leadership Sample technologies Diagnostic solutions #1 #1

GROWTH PILLARS TO CONTRIBUTE ≥$2 BN SALES CER IN 2028 15June 17, 2024 Capital Markets Day 2024 CER – Constant exchange rates TB – Tuberculosis (1) Net sales CER target // SHARPEN FOCUS ON GROWTH PILLARS 2028 target(1) 2024 target(1) ≥$200 mn vs. >$110 mn ≥$200 mn vs. >$100 mn ≥$250 mn vs. >$90 mn Growth pillar QuantiFERON QIAGEN Digital Insights (QDI) Bioinformatics to create genomic data insights QIAstat-Dx Syndromic testing for rapid clinical results QIAcuity dPCR Digital PCR for research and clinical Accelerate investments for growth ~3x ~2x ~2x x 2028 net sales CER target vs. 2024 net sales CER target ≥$750 mn vs. >$650 mn ≥$600 mn vs. >$450 mn Sample technologies DNA / RNA isolation and automation Leading blood-based technology for latent TB Build on proven leadership QuantiFERON Growth focus Add new software and build commercial teams Drive investments in AI / new technologies Add new panels in EU (3) and U.S. (7) Build on >4,000 cumulative placements New QIAsymphony and QIAsprint instruments Accelerate in liquid biopsy, microbiome, etc. Convert remaining 60% of latent TB market Expand global customer base with automation >3x increase in sales specialists Add >100 new assays to expand applications

INITIATIVES TO FUEL GROWTH INVESTMENTS AND ACHIEVE ≥31% ADJUSTED OPERATING INCOME MARGIN IN 2028 Capital Markets Day 2024 ~30 dedicated cross-functional AI initiatives, including: Digitization Accelerating growth and efficiency across QIAGEN ~65% digital transaction share enabling touchless orders // DRIVE EFFICIENCY AND DIGITIZATION Foster agility and ownership in decision-making NeuMoDx decision, continue disciplined portfolio management Improve capacity utilization through network optimization Drive key process scalability with S/4HANA upgrade Operational excellence Positioning QIAGEN for stronger profitable growth Site network strategyProcess optimization Organizational design Portfolio streamlining June 17, 2024 16 Manufacturing Regulatory Customer service >6 million website visitors / year with ~20% increase (2019-23)

Strong cash flow and healthy balance sheet FOCUSING ON TARGETED CAPITAL DEPLOYMENT Capital Markets Day 2024 // ENSURE DISCIPLINED CAPITAL ALLOCATION June 17, 2024 17 Committed to a higher level of returns to shareholders Profitable targeted investments Value-creating transactions Shareholder returns Focused M&A Organic investments

Net zero carbon emission target (2050) 36% female leadership (2023) ≥40% target (2027) >50 public health partnerships (2023) ~8,000 compliance trainings completed (2023) EMBRACING ESG FOR ALL STAKEHOLDERS 18June 17, 2024 Capital Markets Day 2024 Top ESG ratings // DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP Business with integrity Environmental responsibility Investing in people Serving society

EXECUTING OUR STRATEGY WITH EMPOWERED QIAGENERS Expand our culture of empowerment Foster accountability and decentralized decision-making Great Place To Work® Certified NOV 2023–NOV 2024 USA U.S. Great Place To Work® Certificada DEC 2022–DEC 2023 MEXICO Mexico UK Poland Great Place To Work® Certificada OCT 2023–OCT 2024 BRASIL Brazil Great Place To Work® Certified JUL 2023–JUL 2024 PHILIPPINES Philippines Great Place To Work® Certified NOV 2021–NOV 2022 INDIA Great Place To Work® Certified OCT 2023–OCT 2024 CHINA China Germany ~6,000 QIAGENers ~50% new top leaders since 2020 19Capital Markets Day 2024June 17, 2024 ~15% with QIAGEN for >15 years India UNITED KINGDOM 2023 CERTIFIED EXCELLENCE IN EMPLOYEE CONDITIONS DEUTSCHLAND GERMANY 2024 CERTIFIED EXCELLENCE IN EMPLOYEE CONDITIONS POLSKA POLAND 2024 CERTIFIED EXCELLENCE IN EMPLOYEE CONDITIONS // DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP

REINVIGORATED LEADERSHIP TEAM DEDICATED TO DELIVER 20 Joined EC in 2015 Thierry Bernard Chief Executive Officer Joined EC in 2018 Jonathan Sheldon Bioinformatics Presenting today Attending today Toralf Haag Joined in 2021 Elaine Mardis Joined in 2014 Eva van Pelt Joined in 2024 Stephen H. Rusckowski Joined in 2023 Ross Levine Joined in 2016 Bert van Meurs Joined in 2024 Eva Pisa Joined in 2022 Elizabeth E. Tallett Joined in 2011 Lawrence A. Rosen Chair Joined in 2013 Metin Colpan Co-founder of QIAGEN Capital Markets Day 2024June 17, 2024 Joined since 2020 Supervisory Board Executive Committee Joined EC in 2023 Fernando Beils Molecular Diagnostics Joined EC in 2022 Antonio Santos Global Operations Joined EC in 2004 Roland Sackers Chief Financial Officer Joined EC in 2023 Nitin Sood Life Sciences Joined EC in 2019 Stephany Foster Human Resources Joined EC in 2019 Jean-Pascal Viola Corp Strategy / Bus. Dev. // DELIVER THROUGH ACCOUNTABLE, EMPOWERED AND REINVIGORATED LEADERSHIP

21Capital Markets Day 2024 STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH Sharpen focus on growth pillars to sustain profitable growth Drive efficiency and digitization to fuel growth investments and profitability Ensure disciplined capital allocation for growth and shareholder value Deliver through accountable, empowered and reinvigorated leadership BPS – Basis points CAGR – Compound annual growth rate CER – Constant exchange rates June 17, 2024 OUR 2028 TARGETS ≥31% Adj. operating income margin CER (2028) ~7% Net sales CER CAGR (2024-28) At least $2 bn net sales CER from pillars in 2028 At least 250 bps adj. operating income margin expansion 2024-28 At least $1 bn of returns to shareholders 2024-28 (absent M&A)

22Capital Markets Day 2024June 17, 2024 Nitin Sood Senior Vice President Life Sciences Business Area LIFE SCIENCES BY QIAGEN ENDLESS POSSIBILITIES WITH DNA AND RNA

Academic labs Government research labs Pharma / Biotech Forensics / Human ID Hospitals / Decentralized healthcare Reference labs Pharma partnerships Public health agencies LEADING FROM THE FIRST STEP IN LAB WORKFLOWS June 17, 2024 Capital Markets Day 2024 Samples Detection InsightsSample preparation Any biological sample 23 Diagnostic solutions PCR QIAcuity dPCR Genomics / NGS QIAGEN Digital Insights Sample technologies ~$5-6 bn total addressable market (2024) ~$5-6 bn total addressable market (2024) LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS

STRONG PORTFOLIO BUILDING ON SAMPLE PREP LEADERSHIP June 17, 2024 24Capital Markets Day 2024 Applications Applied testingPharma / TranslationalAcademia / ResearchCustomers Sample technologies PCR Digital PCR NGS BioinformaticsQIAGEN portfolio PCR / Nucleic acid amplification Genomics / NGS Life Sciences Microbiome and infectious disease Human ID / ForensicsBiopharmaCancer research Sample technologies

25 Opportunity Strong demand for advanced, reliable solutions to support Life Sciences research, pharma and applied testing markets Why we win One of the most recognized brands in labs, known for quality and expertise from the first step of molecular workflows June 17, 2024 Capital Markets Day 2024 Strategic priorities Sample technologies Leverage #1 position through new automation solutions and cutting- edge applications QIAcuity dPCR Seize dynamic market opportunities and establish leading position with strategic investments to drive growth ENDLESS POSSIBILITIES WITH DNA AND RNA

June 17, 2024 Capital Markets Day 2024 26 HIGH-QUALITY SAMPLE PREP KEY TO ACCESS DNA AND RNA Low- to high-throughput systems for DNA / RNA purification with varying input volumes Updated automation systems Cutting-edge applications Microbiome Cell and gene therapyLiquid biopsy Multi-omics MRD (Minimal Residual Disease) Multi-plex testing Differentiated solutions for modular, integrated workflows Fast time to result, scalability and ease of use Platform-agnostic consumables Sample technologies Critical step in molecular workflows Laboratory workflow Biological sample PCR dPCR NGS Valuable molecular insights // SAMPLE TECHNOLOGIES ~$1.2 bn Sample technologies 2024 total addressable market Sample technologies

LEADER IN THE FIRST STEP OF LAB WORKFLOWS State-of-the-art automation portfolio Comprehensive consumables portfolio ANY biological sample e.g., tissue, cells, blood, serum, wastewater >350 different sample kits for manual and automated processing DNA / RNA target analytes including variations QIAcube Connect QIAcube HT EZ2 Connect QIAsymphony QIAsymphony Connect QIAsprint Connect In development June 17, 2024 Capital Markets Day 2024 // SAMPLE TECHNOLOGIES 27 >28,000 cumulative instrument placements (>9,000 since 2019) >50,000 annual mentions in peer reviewed publications Key achievements >120 mn QIAGEN preparations sold per year NEW NEW QIAGEN offering highest-quality products and unmatched expertise for sophisticated technologies and simplified sample processing

EXTENDING COMPREHENSIVE AUTOMATION OFFERING June 17, 2024 Capital Markets Day 2024 // SAMPLE TECHNOLOGIES High-throughputLow-throughput Mid-throughput QIAcube Connect Up to 12 samples per run QIAsymphony Up to 96 samples per run 28 Research / applied testing Clinical / trans- lational QIAsprint Connect Up to 192 samples per run Launch 2026 NEW QIAsymphony Connect Up to 96 samples per run Launch 2025 NEW Next-gen liquid biopsy applications Can be integrated into lab network Broadest portfolio of applications EZ2 Connect Up to 24 samples per run >3,300 placements(1)>5,700 placements(1) >14,400 placements(1) (1) Cumulative placements as of year-end 2023, QIAcube Connect placements including QIAcube family, EZ2 Connect placements including EZ1 and EZ2 family Benchtop system Large menu supporting applications Validated and customized protocols

FOCUSED STRATEGY TO DRIVE MID-TERM GROWTH 29June 17, 2024 Capital Markets Day 2024 // SAMPLE TECHNOLOGIES ≥$750 mn Sample technologies net sales CER target (2028) Update mid-throughput automation platform with next-gen applications Update flagship instrument leveraging >3,300 global placements QIAsymphony Connect Launch 2025NEW Enter high-throughput automation market for research QIAsprint Connect Introduce new system building upon popular magnetic bead-based consumables Launch 2026NEW Expand in state-of-the-art applications with new consumables Extend #1 position with improved handling through new consumables kits MicrobiomeLiquid biopsy Pathogen detection CER – Constant exchange rates

dPCR – CAPTURING SHARE FROM qPCR AND NGS MARKETS June 17, 2024 30 Quantitative PCR (qPCR) e.g., Cell and Gene Therapy Next-generation sequencing (NGS) e.g., liquid biopsy QIAcuity dPCR Enabling novel applications ~$1.7 bn NGS consumables 2024 total addressable market(1) Lower sensitivity and precision In-depth insights and high precisionHigh sensitivity and precision More accurate than qPCR Fast time-to-result at low cost Slow time-to-result at high cost Rapid and cost-effective Faster and lower cost than NGS ~$2.5 bn qPCR 2024 total addressable market(1) ~$0.5 bn dPCR 2024 total addressable market(1) >15% CAGR (2024-28) // QIAcuity dPCR Capital Markets Day 2024 QIAcuity dPCR (1) Total addressable market incl. research and clinical customer segments (QIAGEN market estimates)

Key achievements TARGETING RESEARCH TO CLINICAL HEALTHCARE 31June 17, 2024 Capital Markets Day 2024 QIAcuity One QIAcuity Four QIAcuity Eight Ease of use Fully integrated automation portfolio Scalable systems Low- to high- throughput capabilities Fastest time to result Over twice as fast vs. droplet digital PCR >2,000 cumulative placements since launch >400 customers with multiple instruments (2024) >350 publications referencing QIAcuity dPCR (2024) >2,300 validated QIAcuity dPCR assays GeneGlobe custom assay design tool Translational and cancer research Exploring use of dPCR vs. NGS Biopharma Precision / speed benefits vs. qPCR / NGS Academia Overcoming entry barrier vs. qPCR // QIAcuity dPCR

SIGNIFICANT INVESTMENTS INTO QIACUITY DPCR 32Capital Markets Day 2024 Add >100 assays menu expansion for CGT, pathogen and cancer research Maximize value of GeneGlobe >10 million predesigned assays with unlimited customization >3x increase of sales specialists for market penetration Accelerate market through customer education in biopharma and translational June 17, 2024 QIAcuity-Dx version for clinical customers Launch BCR-ABL assay with initial focus on hemato-oncology Accelerate commercialization Target new applications Extend into clinical use // QIAcuity dPCR NEW NEW CER – Constant exchange rates CGT – Cell and Gene Therapy ≥$250 mn QIAcuity net sales CER target (2028) FDA submission 2025 NEW Launch 2024 NEW

33June 17, 2024 Capital Markets Day 2024 CAR – Chimeric Antigen Receptors CGT – Cell and Gene Therapy CNV – Copy Number Variation gDNA – Genomic DNA CASE STUDY CAR-T therapy Revolutionary targeted cancer treatment Patient's T-cells are collected and modified to recognize and destroy cancer cells Need for rigorous testing and monitoring to ensure success Comprehensive portfolio desired to obtain in-depth insight and efficiency benefits U.S. children's hospital QIAcuity-enabled vector release assay included in FDA submission ENABLING ACCURATE THERAPY One-stop shop ensuring high quality and support Highest quality and complete line of automation options Compliant with FDA requirements without modifications QIAcuity Copy Number Variation AnalysisQIAamp gDNA extraction QIAcuity Four with QIAcuity CGT / CNV assays Data analysis and interpretation Sample preparation Digital PCR // QIAcuity dPCR

34Capital Markets Day 2024 LIFE SCIENCES ENDLESS POSSIBILITIES WITH DNA AND RNA Sample technologies Leverage #1 position through new automation solutions and cutting-edge applications QIAcuity dPCR Seize dynamic market opportunities and establish leading position with strategic investments to drive growth NET SALES 2028 TARGETS(1) June 17, 2024 Sample technologies ≥$750 mn vs. >$650 mn (2024) QIAcuity dPCR ≥$250 mn vs. >$90 mn (2024) CER – Constant exchange rates (1) Net sales CER target

35Capital Markets Day 2024June 17, 2024 Fernando Beils Senior Vice President Molecular Diagnostics Business Area MOLECULAR DIAGNOSTICS BY QIAGEN DECISIVE WHEN IT MATTERS

ENABLING LABS THROUGH MOLECULAR TESTING June 17, 2024 Capital Markets Day 2024 Samples Detection InsightsSample preparation Any biological sample 36 PCR QIAcuity dPCR Genomics / NGS QIAGEN Digital Insights Sample technologies Diagnostic solutions QuantiFERON | QIAstat-Dx Academic labs Government research labs Pharma / Biotech Forensics / Human ID Hospitals / Decentralized healthcare Reference labs Pharma partnerships Public health agencies ~$5-6 bn total addressable market (2024) ~$5-6 bn total addressable market (2024) LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS

FOCUSING ON UNMET MEDICAL NEEDS 37June 17, 2024 Capital Markets Day 2024 Infectious diseases Oncology Genomic testing Molecular Diagnostics Reference / national labs Hospitals Physicians / clinical labs PharmaPublic health authorities Multiplex syndromic testing Sample technologies Digital PCR BioinformaticsQIAGEN portfolio Blood-based disease detection Sample technologies Diagnostic solutions Genomics / NGS PCR / Nucleic acid amplification Applications Customers

Opportunity Targeting fast-growing markets with demand for novel diagnostics Strategic priorities Why we win Top leadership positions through a differentiated portfolio in areas with unmet medical needs QuantiFERON Expand #1 latent Tuberculosis (TB) position through skin test conversion and complete automation advantages QIAstat-Dx Achieve #2 position with broader global presence and differentiated test menu 38June 17, 2024 Capital Markets Day 2024 DECISIVE WHEN IT MATTERS

June 17, 2024 1 in 4 people have a latent TB bacterial infection Latent TB testing stops spread of active TB and protects public health Broad health risk North America ~35 mn EMEA ~10 mn Asia- Pacific ~15 mn Japan ~7 mn Latin America ~8 mn Capital Markets Day 2024 TUBERCULOSIS: A HIGHLY CONTAGIOUS AND LETHAL BACTERIAL INFECTION 1 in 10 of these people will develop an active TB bacterial infection #1 cause of death among infectious diseases 39 TB – Tuberculosis // QuantiFERON >75 mn latent TB tests annuallyStudents Teachers Visitors / residents of countries with TB Contacts of active TB cases Nursing homesDrug users Immunocompromised patients ~$1.5 bn latent TB testing 2024 total addressable market Healthcare workers Military Global relevance QuantiFERON TB outbreaks

BEST-POSITIONED LATENT TUBERCULOSIS TEST June 17, 2024 Capital Markets Day 2024 >125 mn QuantiFERON-TB tests since launch Key achievements WHO endorsement for QuantiFERON-TB >2,700 citations in publications underscoring clinical value >130 countries with QuantiFERON customers >120 patents in 34 countries beyond 2030 >3 endorsements including WHO, U.S. CDC and IPPA CDC – U.S. Centers for Disease Control and Prevention IPPA – International Panel Physicians Association WHO – World Health Organization 40 // QuantiFERON Advantages to blood-based competitors Advantages to skin test $408 mn 2023 net sales (+70% vs. 2019) Specification QuantiFERON blood test Tuberculin skin test Customizable automated workflow High accuracy and specificity Only one patient visit Electronic results Quality-assured laboratory test

DRIVING SKIN TEST CONVERSION WITH UNRIVALED AUTOMATION 41Capital Markets Day 2024 Skin tests Blood-based tests QuantiFERON Others ~70–80% June 17, 2024 // QuantiFERON Drive TB market conversion Increase customer base Automated liquid handling Automated assay and result New decentralized TB test for emerging markets ~40% ~60% Partnership with Diasorin to expand into Lyme disease ≥$600 mn QuantiFERON net sales CER target (2028) ~$1.5 bn market size(1) Leading automation advantage Large potential in skin test conversion CER – Constant exchange rates (1) Latent tuberculosis testing market (2024)

IDENTIFYING UNKNOWN DISEASES AT SPEED AND EASE June 17, 2024 Capital Markets Day 2024 42 Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Slow diagnosis and treatment decisions can lead to complexities Syndromic testing Fast diagnosis enabling better treatment decisions Day 1 Day X Multiple tests to identify disease Late diagnosis and delay in starting the right treatment One test within one hour Quick diagnosis for accurate treatment GI – Gastrointestinal ~$2.0 bn syndromic testing 2024 total addressable market // QIAstat-Dx QIAstat-Dx Better for patients and physicians Reduces healthcare costs Day 1

QIASTAT-DX OFFERS DIFFERENTIATED FEATURES June 17, 2024 Capital Markets Day 2024 >4,000 cumulative placements since launch ~100 countries with QIAstat-Dx customers Key achievementsKey differentiators >50% of customers use more than 2 panel types 43 Workflow efficiency and safety for robust results Additional pathogens on panels for broader coverage Lab connectivity for remote results Lower noise level for better lab environment // QIAstat-Dx Specification QIAstat-Dx Competition Hands-on time ~1 min >5 min qPCR Amplification curves / Ct values Time to result ~1 hour ~1 hour Strong product capabilities

EXPANDING GLOBAL PRESENCE AND DIFFERENTIATED MENU 44Capital Markets Day 2024 CER – Constant exchange rates cUTI – Complicated Urinary Tract Infection GI – Gastrointestinal Resp. – Respiratory (1) Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), Rhinovirus, SARS-CoV-2 version (2) Campylobacter, Salmonella, Shiga-like toxin E. coli (STEC), Shigella, Yersinia enterolitica or Norovirus versions 202X: Submission date Already launched Mini PanelsComplete Panels Resp. 5 Mini(1) 2x GI 5 Mini(2) 2024 2024 Respiratory GI Meningitis Blood culture cUTIs Pneumonia 2025 2026 2028 2024 2025 2026 2028 ≥$200 mn QIAstat-Dx net sales CER target (2028) June 17, 2024 Drive menu expansion Large hospital networks National reference labs Medium hospitals Regional reference labs Small hospitals Public health labs High-throughput customers Low-throughput customers Grow installed customer base // QIAstat-Dx NEW NEW FDA submission 2024

OFFERING NEW SOLUTIONS FOR PHARMA PROJECTS 45 // QIAstat-Dx AND QIAcuity-Dx MASH – Metabolic dysfunction-associated steatohepatitis Capital Markets Day 2024June 17, 2024 #1 trusted Pharma partner >30 master collaboration agreements 14 FDA approvals QIAstat-Dx for genetic and other diseases Neurological disorders Kidney diseaseMASH Gastrointestinal disease 2 Pharma partnerships New Precision Medicine targets in hereditary diseases NEW QIAcuity-Dx dPCR for Precision Medicine QIAcuity dPCR NGS QDI Unique offering for companion diagnostics Sample to Insight 3 Pharma partnerships QIAsymphony QIAcube EZ2 RGQ qPCR NEW Sample technologies Detection Analysis

46Capital Markets Day 2024June 17, 2024 QuantiFERON Expand #1 latent TB position through skin test conversion and complete automation advantages QIAstat-Dx Achieve #2 position with broader global presence and differentiated test menu MOLECULAR DIAGNOSTICS DECISIVE WHEN IT MATTERS QuantiFERON ≥$600 mn vs. >$450 mn (2024) QIAstat-Dx ≥$200 mn vs. >$100 mn (2024) CER – Constant exchange rates (1) Net sales CER target NET SALES 2028 TARGETS(1)

47Capital Markets Day 2024June 17, 2024 COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024 BREAK

48Capital Markets Day 2024June 17, 2024 Jonathan Sheldon Senior Vice President QIAGEN Digital Insights Business Area BIOINFORMATICS BY QIAGEN POWERFUL ANALYTICS TO UNDERSTAND GENOMICS

ANCHORING GENOMICS OFFERING WITH LEADING SOFTWARE June 17, 2024 Capital Markets Day 2024 Samples Detection InsightsSample preparation Any biological sample 49 PCR Genomics / NGS QIAGEN Digital Insights Sample technologies Diagnostic solutions Academic labs Government research labs Pharma / Biotech Forensics / Human ID Hospitals / Decentralized healthcare Reference labs Pharma partnerships Public health agencies ~$5-6 bn total addressable market (2024) ~$5-6 bn total addressable market (2024) LIFE SCIENCES CUSTOMERS MOLECULAR DIAGNOSTICS CUSTOMERS

QIAGEN UNLOCKING THE POWER OF GENOMICS 50 Development In 2003, the first human genome took 13 years 2000 2010 2020 2030 Sequencing costs Genomic data June 17, 2024 Capital Markets Day 2024 Today, any human genome can be read in 5 hours QDI: #1 in solving the bioinformatics challenge Every day 90,000 users gain valuable disease insights Every month 65,000 reports created by our clinical customers The challenge: Bottleneck in scaling data interpretation Up to 324 million possible variants Research at ~1 hour per variant $100 / sequencing run>$1 bn / genome

51Capital Markets Day 2024 Opportunity High-growth bioinformatics market driven by genomics data expansion and advancements in genetic testing and AI Why we win • Highly profitable Software-as-a-Service business with top margins • Strong #1 position from research to clinical customers • Unique competitive edge with hybrid AI / human curated knowledge base Deepen global commercial reach Extend leadership in curated knowledge Strategic priorities Invest in new AI and other technologies POWERFUL ANALYTICS TO UNDERSTAND GENOMICS June 17, 2024

2024 2028 >10% CER CAGR Bioinformatics market size(1) Strong market opportunity Key growth drivers Genetic testing advancements providing time and cost efficiencies Explosion of genomic data generated by NGS systems Demand for high quality genomics software for data mining Advancements in AI improving efficiency and offering novel insights June 17, 2024 Capital Markets Day 2024 CAPTURING SIGNIFICANT BIOINFORMATICS MARKET GROWTH 52 // HIGH-GROWTH MARKET CAGR – Compound annual growth rate CER – Constant exchange rates NGS – Next-generation sequencing (1) Assessment based on vendors directly relevant to QIAGEN Digital Insights (excludes computing and storage segments) ~$0.6 bn ~$1.0 bn Explosion of genomic data generated by NGS systems Advancements in AI improving efficiency and offering novel insights

#1 LEADING FROM RESEARCH TO CLINICAL CUSTOMERS June 17, 2024 Capital Markets Day 2024 53 #1 in Bioinformatics NGS – Next-generation sequencing Software insights drive the next actions Library prep BioinformaticsNGS analysisSample prep QIAGEN Digital Insights QIAGEN kits NGS partnersQIAGEN kits Addressing large customer base 6 market-leading products >70 countries Research – Scientific discovery Clinical – Patient outcomes Pharma / Biotech Academia Government research Clinical testing labs Hospitals Government labs // STRONG #1 POSITION Delivering QDI software solutions for NGS workflow

54 Pharma challenge QDI pivotal to drug discovery June 17, 2024 Capital Markets Day 2024 CASE STUDY: RESEARCH Key to understanding disease pathways, targets and measure changes Over 50,000 scientific publications cite our software 24 of the Top 25 Pharma companies use QDI Drug research market is worth $60 bn with significant growth expected Significant number of failures without the ability of foresight Within 2 minutes, software indicates specific diseases that could be treated ADVANCING DRUG DEVELOPMENT // STRONG #1 POSITION

55 Patient situation June 17, 2024 Capital Markets Day 2024 CASE STUDY: CLINICAL QDI-enhanced patient outcome QIAGEN Clinical Insights report Profile Male (early 70s) Diagnosis Leukemia linked to rare gene mutation Therapy outlook Standard chemotherapy not expected to be effective Mutation identification and recommendation by QDI ENHANCING PATIENT OUTCOMES Targeted therapy leading to life-saving disease remission // STRONG #1 POSITION

Capital Markets Day 2024 ~$100 mn QDI net sales (2023) 56 >80% annual recurring from subscription-based model Highly profitable QDI business well above comparable peers Market position Research Share of net sales QCI Secondary Analysis COSMIC QCI Precision Insights QCI Interpret OmicSoft COSMIC Human Gene Mutation QIAGEN IPAQIAGEN CLC OFFERING UNIQUELY PROFITABLE SOFTWARE-AS-A-SERVICE PORTFOLIO Clinical Share of net sales #1 #1 #1 #1 #1 #1 Human Gene Mutation #1 #1 // HIGHLY PROFITABLE BUSINESS # June 17, 2024 #1 (1) Launched in 2024 ~40% ~60% NEW (1) Data analysis Data interpretation

June 17, 2024 Capital Markets Day 2024 57 SUSTAINED COMPETITIVE EDGE WITH CURATED KNOWLEDGE >50,000 scientific citations in top journals IPA leadership Clinical leadership >40 scientific and clinical databases leveraging proprietary QIAGEN data Gold standard databases IPA – Ingenuity Pathway Analysis >150 Ph.D. scientists ensuring depth, breadth and quality of knowledge AI with human curation AI enables scale of knowledge databases Augmented human curation ensures trust and confidence Breaking data silos and integrating knowledge sources // UNIQUE COMPETITIVE EDGE >7 mn oncology and hereditary disease variants curated from literature >100,000 scientific publications citing QDI products Scientific applications Databases include gene variants, omics and biomedical

INVESTING TO EXTEND MARKET LEADERSHIP 58June 17, 2024 Capital Markets Day 2024 SaaS – Software-as-a-Service Expand QIAGEN knowledge base into spatial, proteomics and microbiome >12 mn relevant genomic variants for analytics Extend leadership in curated knowledge Deepen global commercial reach Invest in new AI and other technologies NEW ≥$200 mn QDI net sales CER target (2028) Adopt SaaS go-to-market approach >40% new sales specialists dedicated to SaaS sales Continue advancing software portfolio ~20% of QDI sales to be invested into R&D NEW

EXPANDING AI LEADERSHIP WITH PRODUCT INNOVATIONS 59June 17, 2024 Capital Markets Day 2024 4+ upgraded AI-assisted applications NEW 4+ AI-created databases beyond genomics NEW 6+ AI-enabled features including two Software- as-a-Service solutions NEW >14 AI-enabled applications by 2028 Accelerate decision-making with enhanced AI features Enhance knowledge base through extended AI curation Generate innovative insights leveraging AI 5 AI-enabled offerings today New AI-enabled offering AI-enhanced products Pathway analysis Raw genomic data processing Experimental genomic data matching Clinical importance ranking Biomedical Knowledge Base Spatial Genomics Knowledge Base Proteomics Knowledge Base Microbiome Knowledge Base AI-inferred biological targets COVID virtual pathway explorer Rare disease clinical insights Adverse events prediction Drug repurposing prediction AI-enabled pathway querying

60June 17, 2024 Capital Markets Day 2024 QIAGEN DIGITAL INSIGHTS POWERFUL ANALYTICS TO UNDERSTAND GENOMICS Invest in new AI and other technologies Continue advancing software portfolio Extend leadership in curated knowledge Expand breadth of knowledge base Deepen global commercial reach Adopt SaaS go-to-market approach QDI ≥$200 mn vs. >$110 mn (2024) CER – Constant exchange rates (1) Net sales CER target NET SALES 2028 TARGETS(1)

2028 TARGETS COMMITTED TO SOLID PROFITABLE GROWTH 61Capital Markets Day 2024June 17, 2024 Roland Sackers Chief Financial Officer

62Capital Markets Day 2024 STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH Sharpen focus on growth pillars to sustain profitable growth Drive efficiency and digitization to fuel growth investments and profitability Ensure disciplined capital allocation for growth and shareholder value Deliver through accountable, empowered and reinvigorated leadership BPS – Basis points CAGR – Compound annual growth rate CER – Constant exchange rates June 17, 2024 OUR 2028 TARGETS At least $2 bn net sales CER from pillars in 2028 At least 250 bps adj. operating income margin expansion 2024-28 At least $1 bn of returns to shareholders 2024-28 (absent M&A) ~7% Net sales CER CAGR (2024-28) ≥31% Adj. operating income margin CER (2028)

DELIVERING SOLID GROWTH SINCE 2019 Total net sales Adjusted diluted EPS Operating cash flow 2019 2023 ~$330 mn ~$460 mn +9% CAGR 2019 2023 ~$1.5 bn ~$2.0 bn +7% CAGR(1) 2019 2023 $1.43 $2.07 +10% CAGR Strong non-COVID growth Improved profitability Healthy cash generation Capital Markets Day 2024June 17, 2024 63 // SUSTAIN PROFITABLE GROWTH (1) Non-COVID sales CAGR 2019-23 in line with total net sales CAGR CAGR – Compound annual growth rate EPS – Earnings per share

SHARPENED PILLARS DRIVING 2028 GROWTH EXPANSION Capital Markets Day 2024 Growth pillars 2028 net sales CER target 2024-28 net sales CER CAGR June 17, 2024 64 Low-teens growthPCR Low-teens growthGenomics / NGS Diagnostic solutions High-single-digit growth(1) Sample technologies Low- to mid- single-digit growth // SUSTAIN PROFITABLE GROWTH QIAcuity dPCR ~$90 mn ≥25% QIAGEN Digital Insights QIAstat-Dx QuantiFERON Sample technologies ≥$250 mn ≥$200 mn ≥$200 mn ≥$600 mn ≥$750 mn CAGR – Compound annual growth rate CER – Constant exchange rates (1) Organic growth excl. NeuMoDx Accelerate investments for growth Build on proven leadership 2024-28 CAGR >25 >15% ~20% ~7% ~3-4% >15% >10% ~8% ~4-5% ~2-3% QIAGEN Market Product groups 2024-28 net sales CER CAGR

EFFICIENCY AND DIGITAL INITIATIVES DRIVING PROFITABILITY Adjusted operating income margin CER // DRIVE PERFORMANCE AND PROFITABILITY Capital Markets Day 2024June 17, 2024 Initial 2024 target NeuMoDx decision Updated 2024 target Gross margin R&D SG&A 2028 target ≥ 28% +50 bps ≥ 28.5% ≥ 31% ≥+250 bps improvement ≥+100 bps ~+50 bps ≥+100 bps 65 BPS – Basis points Focused investments into QIAcuity, QDI and QIAstat-Dx Targeted organizational simplificationVerogen site integration, NeuMoDx site closure and technology hub strategy Lean manufacturing initiatives and improved supply chain planning AI in product development, performance evaluation and post-market surveillance Customer touchpoint optimization and ERP system efficiencies Digitization and ESG commitments NeuMoDx decision, continued disciplined portfolio management Portfolio streamlining Process optimization and digitization Site network strategy Innovation investments Organizational design Accelerated growth pillars Digitization deep diveOperational excellence deep dive

OPERATIONAL EXCELLENCE: FOSTERING EFFICIENCY Capital Markets Day 2024June 17, 2024 Organizational design Portfolio streamlining Process optimization Site network strategy Multi-year QIAefficiency program Enabling ≥31% adjusted operating income margin in 2028 while fueling growth through targeted investments 66 // DRIVE PERFORMANCE AND PROFITABILITY Leverage gains ~$3 mn annual savings from decentralized empowerment combined with centralized leverage NeuMoDx discontinuation +50 bps adjusted operating income margin gain in H2 2024, further gains with full implementation (end 2025) New sourcing platform ~50-70% automation benefits for ~30,000 manual purchase orders per year ~$5 mn annual savings from online auctioning of freight lanes Verogen site integration ~$3 mn annual savings from Verogen site into QIAGEN Maryland hub Spotlight examples BPS – Basis points

DIGITIZATION: LEVERAGING AI TECHNOLOGY ACROSS QIAGEN Capital Markets Day 2024June 17, 2024 67 // DRIVE PERFORMANCE AND PROFITABILITY Selected areas Manufacturing Regulatory Customer service Spotlight examples Impact Improve efficiencies through AI and digitization across the value chain ~10-15% scrap reduction ~60-70% faster report generation and improved accuracy ~15% reduced hands-on time for ~75,000 tickets processed annually Real-time in-process control and enhanced predictive analytics for production planning Improved accuracy and efficiency in post-market surveillance reporting Proprietary ServiceGPT to reduce hands-on time for processing customer requests

HEALTHY BALANCE SHEET ENABLING CAPITAL ALLOCATION 500 500 105 117 2024 2025 2027 2029 2032 2035 $605 mn $57 mn $617 mn $154 mn $19 mn $77 mn Capital Markets Day 2024 German private placements (Schuldschein) Convertible bonds // ENSURE DISCIPLINED CAPITAL ALLOCATION June 17, 2024 Likely repayment in 2025(2) Debt maturity overview(1) 68 May consider opportunistic refinancing (1) As of December 31, 2023 (2) Bondholder put option in December 2025

PROVEN DISCIPLINED CAPITAL ALLOCATION APPROACH Capital Markets Day 2024June 17, 2024 69 At least $1 bn of returns to shareholders planned for 2024-28 (absent M&A) Value-creating transactions to enhance portfolio and maintain leadership Shareholder returns Focused M&A Organic investments Strong cash flow and healthy balance sheet // ENSURE DISCIPLINED CAPITAL ALLOCATION Profitable targeted investments into pillars and digitization to fuel profitable business expansion

2024-2028 ASSUMPTIONS Capital Markets Day 2024June 17, 2024 Adjusted tax rate: Moderate changes expected subject to legislation (OECD Pillar Two) Net interest income (expense): Reduced interest income, subject to interest rate environment and refinancing opportunities Shares outstanding: ~210-215 mn in 2028(1) 70 Net sales: Business excluding NeuMoDx (1) Subject to share price development and refinancing opportunities OECD – Organization for Economic Cooperation and Development

71Capital Markets Day 2024 STRATEGY: COMMITTED TO SOLID PROFITABLE GROWTH Sharpen focus on growth pillars to sustain profitable growth Drive efficiency and digitization to fuel growth investments and profitability Ensure disciplined capital allocation for growth and shareholder value Deliver through accountable, empowered and reinvigorated leadership BPS – Basis points CAGR – Compound annual growth rate CER – Constant exchange rates June 17, 2024 OUR 2028 TARGETS ≥31% Adj. operating income margin CER (2028) ~7% Net sales CER CAGR (2024-28) At least $2 bn net sales CER from pillars in 2028 At least 250 bps adj. operating income margin expansion 2024-28 At least $1 bn of returns to shareholders 2024-28 (absent M&A)

BUILDING SUSTAINABLE ECOSYSTEMS FOR OUR CUSTOMERS Capital Markets Day 2024June 17, 2024 72 QIAcuity dPCR QIAstat-Dx QIAGEN Digital Insights Sample technologies QuantiFERON Pharma / CROs Public agencies Academia / hospitals Clinical labs / test facilities

73Capital Markets Day 2024June 17, 2024 COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024 Q&A SESSION

COMMITTED TO SOLID PROFITABLE GROWTH Capital Markets Day June 17, 2024